The artificial intelligence (AI)-enabled software Lumina 3D reportedly provides reconstructions of computed tomography angiography (CTA) images of the head and neck in minutes.
While manual reconstruction of computed tomography angiography (CTA) images may take hours to complete, the Food and Drug Administration (FDA) has granted 510(k) clearance to Lumina 3D™, an artificial intelligence (AI) software that offers three-dimensional (3D) reconstructions of the head and neck within minutes.
Exclusively deployed on RapidAI’s Rapid Edge Cloud platform, Lumina 3D allows neuroradiologists to see enhanced visualization of a patient’s aortic arch, carotid artery tortuosity and neurovasculature on mobile devices, according to RapidAI.
Here one can see the use of the newly FDA-cleared Lumina 3D™ software. The AI-powered software provides 3D reconstructions within minutes of obtaining a computed tomography angiography (CTA) scan of the head and neck, according to RapidAI, the developer of Lumina 3D. (Image courtesy of RapidAI.)
The company emphasized that the enhanced imaging capabilities with Lumina 3D reduce procedure times through enhanced accuracy with pre-op planning and catheter selection.
“With a 98% DICE score and results available in minutes, Lumina 3D's level of automation, speed, and accuracy is unprecedented. We are entering an era of precise procedural planning where initial device selection is optimized for individual patient anatomy. … This is a technology that delivers not just better imaging, but potentially better outcomes,” said Daniel Gibson, M.D., a neuro-interventional radiologist affiliated with Goodman Campbell Brain and Spine in Carmel, Ind.
• “Study: AI Model Significantly Enhances CTA Workflow Efficiency and Detection for Cerebral Aneurysm”
• “New Study Assesses Benefits of High-Resolution Photon-Counting for Computed Tomography Angiography”
• “What New Research Reveals About Deep Learning and CT Angiography Detection of Cerebral Aneurysms”
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
